Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.

Felix José Alvarez Ramires,Felipe Martinez,Efrain Gomez,Caroline Demacq,Claudio Gimpelewicz,Jean L. Rouleau,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Milton Packer,John J.V. McMurray

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.

2018

Felix José Alvarez Ramires
Felipe Martinez
Efrain Gomez
Caroline Demacq
Claudio Gimpelewicz
Jean L. Rouleau
Scott D. Solomon
Karl Swedberg
Michael R. Zile
Milton Packer
John J.V. McMurray

Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.

Keywords:

Ivabradine
Chagas Cardiomyopathy
Heart disease
Heart failure
Post-hoc analysis
Cardiology
Internal medicine
Medicine
Chagas disease
post hoc
safety profile

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations